Rockefeller Financial Services’s Alexion Pharmaceuticals ALXN Stock Holding History

Rockefeller Financial Services’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$1.02M	Hold	8,550	–	–	0.02%	227
2017 Q3	$1.2M	Hold	8,550	–	–	0.02%	190
2017 Q2	$1.04M	Sell	8,550 -707	-8%	-$82.3K	0.02%	184
2017 Q1	$1.12M	Hold	9,257	–	–	0.02%	180
2016 Q4	$1.13M	Hold	9,257	–	–	0.02%	185
2016 Q3	$1.13M	Hold	9,257	–	–	0.02%	180
2016 Q2	$1.08M	Hold	9,257	–	–	0.02%	195
2016 Q1	$1.29M	Sell	9,257 -2,888	-24%	-$424K	0.03%	175
2015 Q4	$2.32M	Sell	12,145 -3,081	-20%	-$538K	0.05%	147
2015 Q3	$2.38M	Sell	15,226 -230,327	-94%	-$42M	0.05%	142
2015 Q2	$44.4M	Buy	245,553 +48,546	+25%	+$8.38M	0.92%	36
2015 Q1	$34.1M	Buy	197,007 +9,183	+5%	+$1.66M	0.74%	39
2014 Q4	$34.8M	Buy	+187,824	New	+$34.8M	0.76%	39
2014 Q3	–	Sell	-241,103	Closed	-$37.7M	–	609
2014 Q2	$37.7M	Sell	241,103 -109,333	-31%	-$17.3M	0.85%	43
2014 Q1	$53.3M	Buy	350,436 +1,800	+0.5%	+$286K	1.15%	30
2013 Q4	$46.3M	Sell	348,636 -109,196	-24%	-$13.1M	1%	35
2013 Q3	$53.2M	Sell	457,832 -49,143	-10%	-$5.39M	1.24%	26
2013 Q2	$46.8M	Buy	+506,975	New	+$48.9M	1.12%	29

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rockefeller Financial Services's ALXN Position: Q4 2017 in Review

Rockefeller Financial Services held its Alexion Pharmaceuticals (ALXN) position steady in Q4 2017 at 8,550 shares worth $1.02M. The position accounts for 0.02% of the portfolio, ranked #227.

Rockefeller Financial Services first reported a position in ALXN in Q2 2013 and has held it in 18 quarters since. The position peaked at $53.3M in Q1 2014. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

Rockefeller Financial Services held 8,550 shares of Alexion Pharmaceuticals worth $1.02M as of Q4 2017.
Rockefeller Financial Services left its Alexion Pharmaceuticals share count unchanged in Q4 2017.
Alexion Pharmaceuticals made up 0.02% of Rockefeller Financial Services's portfolio in Q4 2017, its #227 holding.
Rockefeller Financial Services first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 18 quarters since.
Rockefeller Financial Services's Alexion Pharmaceuticals position peaked at $53.3M in Q1 2014.
587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Rockefeller Financial Services's 13F filing for Q4 2017, filed 2 Feb 2018.